Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis

Background: The Functional Assessment of Multiple Sclerosis (FAMS) is widely used in clinical trial programmes; however, it was developed before the rise in trials targeted at early stage multiple sclerosis (MS) and clinically isolated syndrome (CIS). Objective: The aim of this study was to assess the psychometric properties of the FAMS within two clinically distinct populations, CIS and early relapsing–remitting MS (RRMS), and discern the appropriateness of the FAMS within these populations. Methods: Secondary analysis was conducted on FAMS data from two clinical trials assessing interferon beta–1b in early RRMS and CIS. The statistical analysis assessed the scale acceptability, reliability, validity and responsiveness of the FAMS. Item response theory (IRT) was also conducted on the early RRMS sample in order to assess how well the FAMS discriminated amongst individuals with less severe MS. Results: Results from both trials demonstrated an improvement in the FAMS psychometric properties with increased baseline disease severity. However, high ceiling effects were evident amongst less severe patients, and there was an overall lack of responsiveness to improvement and poor construct validity. IRT also demonstrated its lack of discrimination/sensitivity in early RRMS. Conclusions: In trials involving patients with early stage RRMS and CIS, modifications to the FAMS based on a qualitative assessment of its content validity in these populations would be required in order to potentially improve the FAMS psychometric properties and sensitivity.

[1]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[2]  M. Filippi,et al.  250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.

[3]  D. Patrick,et al.  The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. , 2009, Contemporary clinical trials.

[4]  A. Giordano,et al.  Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[6]  M. Edelen,et al.  Applying item response theory (IRT) modeling to questionnaire development, evaluation, and refinement , 2007, Quality of Life Research.

[7]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[8]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[9]  A. Thompson,et al.  How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  J F Fries,et al.  The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. , 2005, Clinical and experimental rheumatology.

[11]  G. Zou Quantifying responsiveness of quality of life measures without an external criterion , 2005, Quality of Life Research.

[12]  A. Solari Role of health-related quality of life measures in the routine care of people with multiple sclerosis , 2005, Health and quality of life outcomes.

[13]  A. Thompson,et al.  Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales , 2003, Multiple sclerosis.

[14]  G Cutter,et al.  The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials , 2002, Multiple sclerosis.

[15]  T. Riise,et al.  Quality of life in multiple sclerosis , 1999, Neurology.

[16]  G. Karabatsos,et al.  Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument , 1996, Neurology.

[17]  M. Liang,et al.  Relative responsiveness of condition-specific and generic health status measures in degenerative lumbar spinal stenosis. , 1995, Journal of clinical epidemiology.

[18]  C. McHorney,et al.  Individual-patient monitoring in clinical practice: are available health status surveys adequate? , 1995, Quality of Life Research.

[19]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[20]  F. Samejima Estimation of latent ability using a response pattern of graded scores , 1968 .

[21]  H. Kaiser The Application of Electronic Computers to Factor Analysis , 1960 .

[22]  P. Kline The handbook of psychological testing, 2nd ed. , 1993 .